Patents by Inventor Nicholas C. Smith

Nicholas C. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240094233
    Abstract: The present invention relates to methods, devices and systems for associating consumable data with an assay consumable used in a biological assay. Provided are assay systems and associated consumables, wherein the assay system adjusts one or more steps of an assay protocol based on consumable data specific for that consumable. Various types of consumable data are described, as well as methods of using such data in the conduct of an assay by an assay system. The present invention also relates to consumables (e.g., kits and reagent containers), software, data deployable bundles, computer-readable media, loading carts, instruments, systems, and methods, for performing automated biological assays.
    Type: Application
    Filed: July 18, 2023
    Publication date: March 21, 2024
    Inventors: Jacob N. WOHLSTADTER, Manish KOCHAR, Peter J. BOSCO, Ian D. CHAMBERLIN, Bandele JEFFREY-COKER, Eric M. JONES, Gary I. KRIVOY, Don E. KRUEGER, Aaron H. LEIMKUEHLER, Pei-Ming WU, Kim-Xuan NGUYEN, Pankaj OBEROI, Louis W. PANG, Jennifer PARKER, Victor PELLICIER, Nicholas SAMMONS, George SIGAL, Michael L. VOCK, Stanley T. SMITH, Carl C. STEVENS, Rodger D. OSBORNE, Kenneth E. PAGE, Michael T. WADE, Jon WILLOUGHBY, Lei WANG, Xinri CONG, Kin NG
  • Publication number: 20240071593
    Abstract: Systems and methods are disclosed that provide smart alerts to users, e.g., alerts to users about diabetic states that are only provided when it makes sense to do so, e.g., when the system can predict or estimate that the user is not already cognitively aware of their current condition, e.g., particularly where the current condition is a diabetic state warranting attention. In this way, the alert or alarm is personalized and made particularly effective for that user. Such systems and methods still alert the user when action is necessary, e.g., a bolus or temporary basal rate change, or provide a response to a missed bolus or a need for correction, but do not alert when action is unnecessary, e.g., if the user is already estimated or predicted to be cognitively aware of the diabetic state warranting attention, or if corrective action was already taken.
    Type: Application
    Filed: October 24, 2023
    Publication date: February 29, 2024
    Inventors: Anna Leigh DAVIS, Scott M. BELLIVEAU, Naresh C. BHAVARAJU, Leif N. BOWMAN, Rita M. CASTILLO, Alexandra Elena CONSTANTIN, Rian W. DRAEGER, Laura J. DUNN, Gary Brian GABLE, Arturo GARCIA, Thomas HALL, Hari HAMPAPURAM, Christopher Robert HANNEMANN, Anna Claire HARLEY-TROCHIMCZYK, Nathaniel David HEINTZMAN, Andrea Jean JACKSON, Lauren Hruby JEPSON, Apurv Ullas KAMATH, Katherine Yerre KOEHLER, Aditya Sagar MANDAPAKA, Samuel Jere MARSH, Gary A. MORRIS, Subrai Girish PAI, Andrew Attila PAL, Nicholas POLYTARIDIS, Philip Thomas PUPA, Eli REIHMAN, Ashley Anne RINDFLEISCH, Sofie Wells SCHUNK, Peter C. SIMPSON, Daniel S. SMITH, Stephen J. VANSLYKE, Matthew T. VOGEL, Tomas C. WALKER, Benjamin Elrod WEST, Atiim Joseph WILEY
  • Patent number: 7968695
    Abstract: The present invention provides the recombinant cloning and sequencing of two of the major Eimeria maxima gametocyte antigens having molecular weights of 56 and 82 kDa and the expression of these recombinant antigens in an E. coli expression system using the plasmid pTrcHis. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen. The subject invention also provides two 30 kDa proteins and three 14 kDa proteins from Eimeria maxima gametocytes having at the N-terminal end the amino acid sequence described herein. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen and any of the aforementioned proteins.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: June 28, 2011
    Assignee: Abic Biological Laboratories Ltd.
    Inventors: Sabina I. Belli, Nicholas C. Smith, Michael Wallach
  • Publication number: 20090196888
    Abstract: The present invention provides the recombinant cloning and sequencing of two of the major Eimeria maxima gametocyte antigens having molecular weights of 56 and 82 kDa and the expression of these recombinant antigens in an E. coli expression system using the plasmid pTrcHis. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen. The subject invention also provides two 30 kDa proteins and three 14 kDa proteins from Eimeria maxima gametocytes having at the N-terminal end the amino acid sequence described herein. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen and any of the aforementioned proteins.
    Type: Application
    Filed: May 30, 2008
    Publication date: August 6, 2009
    Inventors: Sabina I. Belli, Nicholas C. Smith, Michael Wallach
  • Patent number: 7462707
    Abstract: The present invention provides an isolated nucleic acid comprising a nucleotide sequence encoding a 250 kDa polypeptide from Sporozoites/Merozoites of Eimeria maxima, or encoding a homolog of the polypeptide, or a complement of the nucleic acid and a method of producing a recombinant 250 kDa polypeptide of the same. The present invention also provides an isolated nucleic acid comprising a nucleotide sequence encoding an immunodominant portion of a 250 kDa polypeptide from Sporozoites/Merozoites of Eimeria maxima having the amino acid sequence described herein, or encoding a homolog of the polypeptide, or a complement of the nucleic acid.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: December 9, 2008
    Assignees: University of Technology, Sydney, Abic Biological Laboratories Teva, Ltd.
    Inventors: David Witcombe, Nicholas C. Smith, Michael Wallach
  • Patent number: 7423137
    Abstract: The present invention provides the recombinant cloning and sequencing of two of the major Eimeria maxima gametocyte antigens having molecular weights of 56 and 82 kDa and the expression of these recombinant antigens in an E. coli expression system using the plasmid pTrcHis. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen. The subject invention also provides two 30 kDa proteins and three 14 kDa proteins from Eimeria maxima gametocytes having at the N-terminal end the amino acid sequence described herein. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen and any of the aforementioned proteins.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: September 9, 2008
    Assignee: Abic Biological Laboratories Teva, Ltd.
    Inventors: Sabina I. Belli, Nicholas C. Smith, Michael Wallach